Novartis AG (NVS)
Automate Your Wheel Strategy on NVS
With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVS
- Rev/Share 28.044
- Book/Share 21.5883
- PB 6.0809
- Debt/Equity 0.7773
- CurrentRatio 0.8179
- ROIC 0.1849
- MktCap 253712918819.0
- FreeCF/Share 8.6273
- PFCF 15.0966
- PE 26.5472
- Debt/Assets 0.3126
- DivYield 0.0305
- ROE 0.2294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVS | Goldman | Neutral | Sell | -- | $118 | Sept. 12, 2025 |
| Upgrade | NVS | Morgan Stanley | Underweight | Equal Weight | -- | $123 | Aug. 8, 2025 |
| Downgrade | NVS | UBS | Buy | Neutral | -- | -- | Feb. 13, 2025 |
| Initiation | NVS | Morgan Stanley | -- | Underweight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVS | Deutsche Bank | Hold | Buy | -- | -- | Feb. 4, 2025 |
| Downgrade | NVS | HSBC Securities | Hold | Reduce | -- | -- | Dec. 4, 2024 |
| Downgrade | NVS | BofA Securities | Buy | Neutral | $135 | $130 | Sept. 11, 2024 |
| Downgrade | NVS | Goldman | Buy | Neutral | -- | -- | Sept. 5, 2024 |
| Downgrade | NVS | Jefferies | Buy | Hold | -- | -- | Sept. 3, 2024 |
News
Here's Why Novartis (NVS) is a Strong Value Stock
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Read More
3 Reasons Growth Investors Will Love Novartis (NVS)
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Novartis (NVS) could produce exceptional returns because of its solid growth attributes.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Why Novartis (NVS) is a Top Momentum Stock for the Long-Term
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Novartis: Superstars Entresto And Kisqali Fuel Market Outperformance
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Positive
Even the launch of generic versions of heart failure blockbuster Entresto and Trump's threats to cut drug prices won't overshadow the strong performance of Novartis AG's oncology franchise. So, sales of Scemblix, which is rapidly capturing the chronic myeloid leukemia market, reached $298 million for NVS in the second quarter of 2025, an increase of 81.7% year-on-year. Also, I was pleased to see that NVS repurchased $2.71 billion worth of its shares in Q2 2025, a 68% increase year-on-year.
Read More
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
Published: September 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Novartis (NVS) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Read More
Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments
Published: September 15, 2025 by: Benzinga
Sentiment: Positive
Monte Rosa Therapeutics Inc. GLUE stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro.
Read More
NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.
Read More
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Negative
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
Published: September 09, 2025 by: Investors Business Daily
Sentiment: Positive
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company for $1.4 billion.
Read More
NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Novartis strikes a $200M licensing deal with Arrowhead for ARO-SNCA, aiming to advance treatments for Parkinson???s Disease.
Read More
New Novartis ESC data highlights strength of cardiovascular portfolio
Published: August 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
PRESS RELEASE Two VictORION studies will highlight Leqvio's impact on patient quality of life, and as a cholesterol lowering monotherapy Lp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing need for lipoprotein apheresis – a cholesterol removal procedure similar to dialysis PARACHUTE-HF study will highlight the efficacy and safety of Entresto to treat heart failure with reduced ejection fraction due to chronic Chagas disease Additional presentations will assess the safety of new pipeline asset abelacimab in atrial fibrillation Basel, August 18, 2025 – Novartis will present data from 19 abstracts across its cardiovascular portfolio at the 2025 European Society …
Read More
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
Published: August 17, 2025 by: The Motley Fool
Sentiment: Negative
Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar competition that erodes their market share.
Read More
Swiss government to meet pharma firms to discuss US tariffs
Published: August 11, 2025 by: Reuters
Sentiment: Neutral
The Swiss government is due to meet this week with pharmaceuticals firms that U.S. President Donald Trump has asked to lower their prices, as Switzerland seeks to negotiate down a new 39% tariff on its exports, two sources have told Reuters.
Read More
Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease
Published: August 11, 2025 by: WSJ
Sentiment: Positive
The pharma company said the drug has the potential to become the first and only targeted treatment approved for patients with Sjoegren's disease.
Read More
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
Published: August 11, 2025 by: PRNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global Phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's disease1 Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren's disease Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease1,2 Novartis plans to present its data at an upcoming medical congress and submit to health authorities globally EAST HANOVER, N.J.
Read More
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease
Published: August 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjögren's disease 1 Ianalumab has the potential to become the first and only targeted treatment approved for patients with Sjögren's disease Ianalumab was well tolerated and demonstrated a favorable safety profile in Sjögren's disease 1, 2 Novartis plans to present its data at an upcoming medical congress and submit to health authorities globally Basel, August 11, 2025 – Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) …
Read More
Novartis weighs deal for biotech Avidity Biosciences, FT reports
Published: August 06, 2025 by: Reuters
Sentiment: Positive
Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter
Read More
Here's Why Novartis (NVS) is a Strong Value Stock
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
Read More
Novartis AG (NVS) Q2 2025 Earnings Call Transcript
Published: July 21, 2025 by: Seeking Alpha
Sentiment: Neutral
Novartis AG (NYSE:NVS ) Q2 2025 Earnings Conference Call July 17, 2025 8:00 AM ET Company Participants Harry Kirsch - Chief Financial Officer Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Conference Call Participants Emmanuel Douglas Papadakis - Deutsche Bank AG, Research Division Florent Cespedes - Societe Generale Cross Asset Research Harry Thomas d'Alton Sephton - Crédit Suisse AG, Research Division James Patrick Quigley - Goldman Sachs Group, Inc., Research Division Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division Michael Leuchten - UBS Investment Bank, Research Division Michael Thomas Nedelcovych …
Read More
Industry-Wide Tariffs Loom Over the Healthcare Sector. Here Are 2 Stocks That Can Weather the Storm.
Published: July 20, 2025 by: The Motley Fool
Sentiment: Negative
President Donald Trump's trade policies have caused tumult on Wall Street. The president has pushed for aggressive tariffs on imported goods in an attempt to bring manufacturing jobs back to the country.
Read More
Buy These 5 Low-Leverage Stocks Amid Impressive Retail Sales Data
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
With retail sales rebounding and Wall Street gaining, low-leverage stocks like NVS, RMD, WAB, ESLT and INGR offer scope for upside.
Read More
Novartis: Q2 Earnings Review - Solid Results Justify All-Time High Share Price
Published: July 17, 2025 by: Seeking Alpha
Sentiment: Positive
Novartis AG delivered strong Q2 2025 results, outpacing expectations, but faces looming patent expiries for major drugs like Entresto, Tasigna, and Promacta. Growth in new and existing pipeline drugs, plus robust financials and buybacks, position Novartis for resilience despite upcoming revenue headwinds. While the company's long-term outlook remains positive, current valuation already reflects its strengths, making shares fairly valued at this time.
Read More
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Published: July 17, 2025 by: CNBC
Sentiment: Positive
Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its Entresto heart failure therapy.
Read More
Novartis slightly raises 2025 earnings forecast, citing strong Q2
Published: July 17, 2025 by: Reuters
Sentiment: Positive
Novartis on Thursday posted a slightly more optimistic full-year earnings forecast, citing the strong growth of drugs such as breast cancer drug Kisqali during the second quarter.
Read More
About Novartis AG (NVS)
- IPO Date 1996-11-07
- Website https://www.novartis.com
- Industry Drug Manufacturers - General
- CEO Vasant Narasimhan
- Employees 75883